FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

研究/Highlighting the potential of GLP1-RA as an effective treatment for weight regain following bariatric surgery and discussing its implications for clinical practice.
研究ライブラリに戻る
GLP1-RALiraglutideSemaglutide

Highlighting the potential of GLP1-RA as an effective treatment for weight regain following bariatric surgery and discussing its implications for clinical practice.

May 17, 2026
Share

元の論文

Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study.

Jensen Anders Boisen et al.Obesity surgery2023
発展中の研究

これらは有望ですが、さらなる検証が必要な発展途上の見解に基づいています。

この分析について

この記事は、上記の元の論文から得られた見解をペプチド研究コミュニティ向けに読みやすく分解しています。私たちの目標は、最も重要な点 — 実践的な意味合い、証拠の強さ、そして継続的研究に対する影響 — を強調することです。

GLP-1 Receptor Agonists Show Promise in Tackling Weight Regain After Bariatric Surgery

Published: May 17, 2026 | Source: Obesity surgery (2023) | Category: GLP1-RA, Liraglutide, Semaglutide

Overview

A recent study published in Obesity Surgery suggests that glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as liraglutide and semaglutide, can help patients who have regained weight after bariatric surgery to lose a significant portion of the regained weight within six months. This finding is crucial for those seeking effective treatments for weight regain following surgical interventions.

Study Background

Weight regain after bariatric surgery is a common issue, affecting up to one-third of patients. While GLP-1 RAs are known to be effective in managing type 2 diabetes and obesity, their role in treating weight regain specifically after bariatric surgery was less clear until now. This retrospective observational study aimed to fill this knowledge gap by examining the efficacy of liraglutide and semaglutide for patients who had regained weight post-surgery.

What the Research Found

The study involved 50 patients (82% female) at a Swiss bariatric reference center, with an average age of 47 years. Before treatment with GLP-1 RAs, these patients had an average body weight of 90.5 kg and a BMI of 34.0 kg/m². After six months of treatment (liraglutide: n=29; semaglutide: n=21), the median weight loss was substantial, with two-thirds of the regained weight being lost.

What This Means for Peptide Users

For individuals who have experienced weight regain after bariatric surgery, this study provides hope and a new therapeutic option. GLP-1 RAs can be an effective tool in helping these patients achieve significant weight loss, thereby improving their overall health outcomes and reducing the risk of obesity-related complications.

Limitations and Caveats

While promising, this study has several limitations that must be acknowledged. It was conducted at a single center with a relatively small sample size, which limits its generalizability to broader populations. Additionally, the retrospective nature of the research means there could be uncontrolled variables influencing the results. Randomized controlled trials are needed to confirm these findings and establish GLP-1 RAs as standard treatment options for weight regain after bariatric surgery.

How This Compares to Previous Research

Previous studies have highlighted the efficacy of GLP-1 RAs in treating obesity and type 2 diabetes, but this is one of the first to focus specifically on their role in managing weight regain post-bariatric surgery. The results align with earlier research showing that these peptides can induce significant weight loss, although the specific context of bariatric surgery adds a new dimension to our understanding.

Our Analysis

PeptideVault views this study as an important step forward in addressing the challenges faced by patients who experience weight regain after bariatric surgery. The findings are encouraging and provide a basis for further research. However, due to the limitations mentioned, it is crucial that future studies employ randomized controlled trial designs to validate these results.

Key Takeaways

  • GLP-1 RAs can help patients lose significant amounts of regained weight within six months after bariatric surgery.
  • The study highlights a need for larger-scale clinical trials to confirm the efficacy and safety of GLP-1 RAs in this specific patient population.
  • For now, healthcare providers should consider these findings as part of an evolving understanding of GLP-1 RA's potential benefits beyond traditional indications like diabetes and obesity.

Original Source

Citation: Jensen Anders Boisen, Renström Frida, Aczél Stefan et al. (2023). Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study.. Obesity surgery. DOI: 10.1007/s11695-023-06484-8

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

編集者の注

この分析はPeptide Contacts研究チームによって作成されました。情報確認のために常に元のソースをご確認ください。 元の論文 詳細な方法論とデータについては 元の出版物は以下で利用可能です PubMed.

関連研究

Comments

Sign in to join the discussion

この分析は査読済みの研究から生成され、教育目的のみで使用されます。医療アドバイスにはなりません。ペプチドベースの治療を使用する前に常に格付けされた医療専門家に相談してください。